Display options
Cite
Wintrob ZA, Hammel JP, Nimako GK, et al. Insulin secretagogue use and circulating inflammatory C-C chemokine levels in breast cancer patients. Data Brief. 2017;11:391-402doi: 10.1016/j.dib.2017.02.031.
Wintrob, Z. A., Hammel, J. P., Nimako, G. K., Fayazi, Z. S., Gaile, D. P., Forrest, A., & Ceacareanu, A. C. (2017). Insulin secretagogue use and circulating inflammatory C-C chemokine levels in breast cancer patients. Data in brief, 11391-402. https://doi.org/10.1016/j.dib.2017.02.031
Wintrob, Zachary A P, et al. "Insulin secretagogue use and circulating inflammatory C-C chemokine levels in breast cancer patients." Data in brief vol. 11 (2017): 391-402. doi: https://doi.org/10.1016/j.dib.2017.02.031
Wintrob ZA, Hammel JP, Nimako GK, Fayazi ZS, Gaile DP, Forrest A, Ceacareanu AC. Insulin secretagogue use and circulating inflammatory C-C chemokine levels in breast cancer patients. Data Brief. 2017 Feb 16;11:391-402. doi: 10.1016/j.dib.2017.02.031. eCollection 2017 Apr. PMID: 28275673; PMCID: PMC5331147.
Copy Download .nbib Format: NLM
Share it on

Data Brief. 2017 Feb 16;11:391-402. doi: 10.1016/j.dib.2017.02.031. eCollection 2017 Apr.

Insulin secretagogue use and circulating inflammatory C-C chemokine levels in breast cancer patients.

Data in brief

Zachary A P Wintrob, Jeffrey P Hammel, George K Nimako, Zahra S Fayazi, Dan P Gaile, Alan Forrest, Alice C Ceacareanu

Affiliations

  1. State University of New York at Buffalo, Dept. of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, USA.
  2. Cleveland Clinic, Dept. of Biostatistics and Epidemiology, 9500 Euclid Ave., Cleveland, OH 44195, USA.
  3. State University of New York at Buffalo, Dept. of Biostatistics, 718 Kimball Tower, Buffalo, NY 14214, USA.
  4. The UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Campus Box 7569, Chapel Hill, NC 27599, USA.
  5. State University of New York at Buffalo, Dept. of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, USA; Roswell Park Cancer Institute, Dept. of Pharmacy Services, Elm & Carlton Streets, Buffalo, NY 14263, USA.

PMID: 28275673 PMCID: PMC5331147 DOI: 10.1016/j.dib.2017.02.031

Abstract

Monocytes' infiltration into the tumor tissue and their activation to tumor-associated macrophages is an essential step in tumor development, also playing a critical role in an eventual metastasis. Stimulation of endogenous insulin production by oral insulin secretagogue treatment has the potential to interfere with the production and release of C-C chemokines, a group of potent inflammatory cytokines acting as monocyte chemo-attractants and influencing their behavior in the tumor microenvironment. Studied plasma samples were collected under a previously reported study design involving a population of women diagnosed with breast cancer presenting with or without type 2 diabetes mellitus at the time of breast cancer diagnosis (Wintrob et al., 2017, 2016) [1,2]. The data presented here shows the relationship between pre-existing use of insulin secretagogue, the inflammatory C-C chemokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis stratified by secretagogue use and controls was implemented to evaluate the relationship between the investigated biomarkers and respectively each of these biomarkers and the other relevant reported cytokine datasets derived from the same patient population (Wintrob et al., 2017, 2016) [1,2].

Keywords: Activated macrophage; Breast cancer; CCL-2; CCL-3; CCL-4; CCL-5; Cancer outcomes; Cancer prognosis; C–C chemokines; Diabetes; Inflammation; Inflammatory cytokines; Monocyte infiltration; Secretagogue

References

  1. Oncotarget. 2016 Apr 26;7(17):24495-509 - PubMed
  2. Cancer Res. 2002 Feb 15;62(4):1093-102 - PubMed
  3. Cancer Res. 1999 Sep 15;59(18):4681-7 - PubMed
  4. Cancer Microenviron. 2013 Aug;6(2):179-91 - PubMed
  5. Oncotarget. 2016 Feb 16;7(7):8389-98 - PubMed
  6. Cytokine. 2012 Oct;60(1):1-12 - PubMed
  7. BMC Clin Pathol. 2013 May 22;13:15 - PubMed
  8. J Biol Chem. 2006 Sep 8;281(36):26602-14 - PubMed
  9. Cytokine. 2017 Jan;89:45-61 - PubMed
  10. Int J Clin Exp Med. 2015 Sep 15;8(9):15684-91 - PubMed
  11. Cancer Res Treat. 2015 Apr;47(2):306-12 - PubMed
  12. Data Brief. 2016 Nov 22;10 :238-247 - PubMed
  13. Cancer Lett. 2016 Aug 1;378(1):23-32 - PubMed

Publication Types

Grant support